GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tong Ren Tang Technologies Co Ltd (HKSE:01666) » Definitions » Capex-to-Operating-Cash-Flow

Tong Ren Tang Technologies Co (HKSE:01666) Capex-to-Operating-Cash-Flow : 0.20 (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Tong Ren Tang Technologies Co Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Tong Ren Tang Technologies Co's Capital Expenditure for the six months ended in Dec. 2024 was HK$-97.94 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2024 was HK$500.19 Mil.

Hence, Tong Ren Tang Technologies Co's Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2024 was 0.20.


Tong Ren Tang Technologies Co Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Tong Ren Tang Technologies Co's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tong Ren Tang Technologies Co Capex-to-Operating-Cash-Flow Chart

Tong Ren Tang Technologies Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.77 0.15 0.23 0.19 11.16

Tong Ren Tang Technologies Co Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.07 - - 0.20

Competitive Comparison of Tong Ren Tang Technologies Co's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - General subindustry, Tong Ren Tang Technologies Co's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tong Ren Tang Technologies Co's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tong Ren Tang Technologies Co's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Tong Ren Tang Technologies Co's Capex-to-Operating-Cash-Flow falls into.


;
;

Tong Ren Tang Technologies Co Capex-to-Operating-Cash-Flow Calculation

Tong Ren Tang Technologies Co's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-185.95) / 16.663
=11.16

Tong Ren Tang Technologies Co's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-97.939) / 500.193
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tong Ren Tang Technologies Co  (HKSE:01666) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Tong Ren Tang Technologies Co Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Tong Ren Tang Technologies Co's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Tong Ren Tang Technologies Co Business Description

Traded in Other Exchanges
Address
No. 16 Tongji Beilu, Beijing Economic and Technological Development Zone, Beijing, CHN
Tong Ren Tang Technologies Co Ltd is engaged in the production and distribution of Chinese medicine and predominantly operates in Mainland China and Hong Kong. The operating segments derive their revenue predominantly from the manufacture and sale of Chinese medicine of the company in Mainland China and Tong Ren Tang Chinese Medicine and its subsidiaries engaged in manufacturing, retail, and wholesale of Chinese medicine products and healthcare products, and provision of Chinese medical consultation and treatments outside Mainland China and wholesale of healthcare products in Mainland China.
Executives
Citigroup Inc. 2502 Approved lending agent
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Aberdeen Asset Management Plc And Its Associates 2102 Investment manager

Tong Ren Tang Technologies Co Headlines

No Headlines